Guillemette E Benoist
Overview
Explore the profile of Guillemette E Benoist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Benoist G, van Oort I, Burger D, Koch B, Mehra N, van Erp N
Eur Urol
. 2018 Sep;
75(2):351-352.
PMID: 30245086
No abstract available.
12.
Benoist G, van der Meulen E, van Oort I, Beumer J, Somford D, Schalken J, et al.
Ther Drug Monit
. 2018 Feb;
40(2):222-229.
PMID: 29419723
Background: Enzalutamide is a potent androgen-signaling receptor inhibitor and is licensed for the treatment of metastatic castration-resistant prostate cancer. N-desmethylenzalutamide is the active metabolite of enzalutamide. A method to quantitate...
13.
Benoist G, van der Doelen M, Ter Heine R, van Erp N, Mehra N
Br J Clin Pharmacol
. 2018 Feb;
84(5):1064-1067.
PMID: 29384591
Adverse Event: Decreased abiraterone exposure after introducing carbamazepine. Drugs Implicated: Abiraterone acetate and carbamazepine. The Patient: A 65-year-old man with metastatic castration resistant prostate cancer, was treated with abiraterone acetate...
14.
Benoist G, van der Meulen E, Lubberman F, Gerritsen W, Smilde T, Schalken J, et al.
Biomed Chromatogr
. 2017 Apr;
31(11).
PMID: 28370076
A method was developed and validated to quantify abiraterone in human plasma. During assay development, several analytical challenges were encountered: limited stability in patient samples, adsorption to glass, coelution with...
15.
Benoist G, Hendriks R, Mulders P, Gerritsen W, Somford D, Schalken J, et al.
Clin Pharmacokinet
. 2016 Apr;
55(11):1369-1380.
PMID: 27106175
Two novel oral drugs that target androgen signaling have recently become available for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Abiraterone acetate inhibits the synthesis of the natural ligands...